Rekambys for HIV-1 infection (maintenance therapy)
Quick answer: Rekambys is used for HIV-1 infection (maintenance therapy) as part of a non-nucleoside reverse transcriptase inhibitor (long-acting injectable) treatment regimen. Long-acting injectable rilpivirine that inhibits HIV-1 reverse transcriptase via non-competitive binding The specific dosing for HIV-1 infection (maintenance therapy) is determined by your prescriber based on individual factors.
Why is Rekambys used for HIV-1 infection (maintenance therapy)?
Rekambys belongs to the Non-nucleoside reverse transcriptase inhibitor (long-acting injectable) class. Long-acting injectable rilpivirine that inhibits HIV-1 reverse transcriptase via non-competitive binding This action makes it useful for treating or managing HIV-1 infection (maintenance therapy) in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Rekambys is the right choice for a specific patient depends on the type and severity of HIV-1 infection (maintenance therapy), response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for HIV-1 infection (maintenance therapy)
Common adult dosing range: 900 mg IM initial then 600 mg IM every 2 months (with cabotegravir). The actual dose for HIV-1 infection (maintenance therapy) depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Rekambys medicine page.
What to expect
Rekambys treatment for HIV-1 infection (maintenance therapy) typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on HIV-1 infection (maintenance therapy)
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Rekambys is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Non-nucleoside reverse transcriptase inhibitor (long-acting injectable) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Rekambys
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Rekambys full prescribing information · All Non-nucleoside reverse transcriptase inhibitor (long-acting injectable) alternatives
Frequently asked questions
How effective is Rekambys for HIV-1 infection (maintenance therapy)?
Effectiveness varies by individual response, dose, and severity. Rekambys is one of several treatment options for HIV-1 infection (maintenance therapy), supported by clinical evidence within the non-nucleoside reverse transcriptase inhibitor (long-acting injectable) class. Discuss expected response with your prescriber.
How long do I need to take Rekambys for HIV-1 infection (maintenance therapy)?
Treatment duration depends on the nature of HIV-1 infection (maintenance therapy) — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Rekambys when used for HIV-1 infection (maintenance therapy)?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Rekambys for HIV-1 infection (maintenance therapy)?
Yes. Multiple medicines and non-drug options exist for HIV-1 infection (maintenance therapy). Alternatives within the non-nucleoside reverse transcriptase inhibitor (long-acting injectable) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.